Skip to main content

Table 3 Association of antidepressant with risk of any or severe steatosis by weighted regression

From: Association between antidepressant use and liver fibrosis in patients with type 2 diabetes: a population based study

Variables

Any steatosis (≥ S1)

Severe steatosis (S3)

 

OR

95%CI

P-value

OR

95%CI

P-value

Sex

1.51

0.88–2.36

0.29

1.81

1.03–3.01

0.04

Age

1.02

0.99–1.05

0.25

1.01

0.99–1.15

0.59

Race

–

–

–

–

–

–

Non-Hispanic white

Ref

–

–

Ref

–

–

Non-Hispanic Black

0.51

0.07–0.89

0.04

0.49

0.17–2.89

0.1

Mexican American

1.54

0.78–3.05

0.21

1.87

0.65–3.0

0.33

Other

1.77

1.0–2.82

0.61

1.58

0.77–2.98

0.79

BMI

1.15

1.07–1.22

0.01

1.11

1.00–1.20

0.06

ALT

1.02

1.01–1.04

0.03

1.03

1.01–1.08

0.05

AST

0.96

0.89–1.0

0.12

0.99

0.99–1.03

0.61

GGT

1.0

0.99–1.01

0.77

1.0

0.99–1.00

0.38

HbA1c

1.21

1.05–1.49

0.03

1.27

0.99–1.51

0.32

Triglycerides

1.01

1.0–1.02

 < 0.001

1.01

1.0–1.02

 < 0.001

LDL

0.87

0.71–1.07

0.18

0.81

0.71–1.11

0.19

Antidepressant use

0.79

0.41–1.84

0.39

0.87

0.39–1.55

0.59

  1. BMI body mass index, ALT alanine transaminase, AST aspartate transaminase, GGT gamma-glutamyl transpeptidase, LDL low density lipoprotein, HbA1c glycosylated hemoglobin;
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us